[Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares April 12, 2019 05:04 PM Eastern Daylight Time BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today provided an updat]
[Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares April 12, 2019 05:04 PM Eastern Daylight Time BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today provided an updat]
[CUSIP No. P8696W104 1. Names of Reporting Persons 1Globe Capital LLC 80-0841812 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ 3. SEC Use Only 4. Source of Funds (See Instructions) WC 5.]
[CUSIP No. P8696W104 1. Names of Reporting Persons 1Globe Capital LLC 80-0841812 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ 3. SEC Use Only 4. Source of Funds (See Instructions) WC 5.]
[Sinovac: Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares March 8, 2019 BEIJING, – Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today issued an update on the Exchange of Rights for Common ]
[Sinovac: Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares March 8, 2019 BEIJING, – Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today issued an update on the Exchange of Rights for Common ]
[Sinovac: Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares March 8, 2019 BEIJING, – Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today issued an update on the Exchange of Rights for Common ]
[Sinovac: Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares March 8, 2019 BEIJING, – Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today issued an update on the Exchange of Rights for Common ]
[Sinovac Determines Trigger Event Occurred Under Rights Agreement · Sinovac Board of Directors Determines Certain Collaborating Shareholders Became Acquiring Persons, Voiding their Preferred Share Purchase Rights; · Valid Preferred Share Purchase Rights Held by all Non-Collaborating Shareholders Exch]
[W ashington FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES SINOVAC BIOTECH LTD. Antigua, West Indies Not Applicable (State or other jurisdiction (I.R.S. Employer Identification of incorporation or organization) Number) No. 15 Zhi Tong Road, Zhongguancun Science and Technology Park Changp]
